{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T16:15:38Z","timestamp":1790957738540,"version":"4.1.0"},"reference-count":145,"publisher":"Springer Science and Business Media LLC","issue":"11","license":[{"start":{"date-parts":[[2020,11,1]],"date-time":"2020-11-01T00:00:00Z","timestamp":1604188800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,11,1]],"date-time":"2020-11-01T00:00:00Z","timestamp":1604188800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2020,8,31]],"date-time":"2020-08-31T00:00:00Z","timestamp":1598832000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Saudi Pharmaceutical Journal"],"published-print":{"date-parts":[[2020,11]]},"DOI":"10.1016\/j.jsps.2020.08.025","type":"journal-article","created":{"date-parts":[[2020,9,12]],"date-time":"2020-09-12T04:00:32Z","timestamp":1599883232000},"page":"1353-1363","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":23,"title":["The potential of Atorvastatin for chronic lung diseases therapy"],"prefix":"10.1007","volume":"28","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9991-7801","authenticated-orcid":false,"given":"Alaa S.","family":"Tulbah","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","reference":[{"issue":"3","key":"10.1016\/j.jsps.2020.08.025_b0005","first-page":"341","article-title":"Solubility and dissolution enhancement of poorly aqueous soluble drug atorvastatin calcium using modified gum karaya as carrier: In vitro-In vivo evaluation","volume":"4","author":"Aggarwal","year":"2012","journal-title":"Int. J. Drug Deliv."},{"issue":"21","key":"10.1016\/j.jsps.2020.08.025_b0010","doi-asserted-by":"crossref","first-page":"6157","DOI":"10.7150\/thno.35805","article-title":"CAV1-GLUT3 signaling is important for cellular energy and can be targeted by Atorvastatin in Non-Small Cell Lung Cancer","volume":"9","author":"Ali","year":"2019","journal-title":"Theranostics"},{"issue":"3","key":"10.1016\/j.jsps.2020.08.025_b0015","first-page":"1081","article-title":"The effect of atorvastatin on bleomycin-induced pulmonary fibrosis in rats","volume":"31","author":"Ali","year":"2018","journal-title":"Menoufia Med. J."},{"issue":"5","key":"10.1016\/j.jsps.2020.08.025_b0020","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1097\/00024382-200005000-00002","article-title":"Unintended immunomodulation: part II. Effects of pharmacological agents on cytokine activity","volume":"13","author":"ALKharfy","year":"2000","journal-title":"Shock"},{"issue":"16","key":"10.1016\/j.jsps.2020.08.025_b0025","doi-asserted-by":"crossref","first-page":"2789","DOI":"10.1517\/14656566.8.16.2789","article-title":"Atorvastatin in prevention of stroke and transient ischaemic attack","volume":"8","author":"Amarenco","year":"2007","journal-title":"Expert Opin. Pharmacother."},{"issue":"3","key":"10.1016\/j.jsps.2020.08.025_b0030","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1165\/ajrcmb.16.3.9070608","article-title":"Expression and localization of CYP3A4 and CYP3A5 in human lung","volume":"16","author":"Anttila","year":"1997","journal-title":"Am. J. Respir. Cell Mol. Biol."},{"issue":"9601","key":"10.1016\/j.jsps.2020.08.025_b0035","doi-asserted-by":"crossref","first-page":"1781","DOI":"10.1016\/S0140-6736(07)60716-8","article-title":"The safety of statins in clinical practice","volume":"370","author":"Armitage","year":"2007","journal-title":"The Lancet"},{"issue":"11","key":"10.1016\/j.jsps.2020.08.025_b0040","doi-asserted-by":"crossref","first-page":"1335","DOI":"10.6061\/clinics\/2012(11)19","article-title":"Airway disease: similarities and differences between asthma, COPD and bronchiectasis","volume":"67","author":"Athanazio","year":"2012","journal-title":"Clinics"},{"issue":"5","key":"10.1016\/j.jsps.2020.08.025_b0045","doi-asserted-by":"crossref","first-page":"704","DOI":"10.1165\/rcmb.2013-0203RC","article-title":"Statins in Lymphangioleiomyomatosis. Simvastatin and atorvastatin induce differential effects on tuberous sclerosis complex 2\u2013null cell growth and signaling","volume":"49","author":"Atochina-Vasserman","year":"2013","journal-title":"Am. J. Respir. Cell Mol. Biol."},{"issue":"2","key":"10.1016\/j.jsps.2020.08.025_b0050","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1016\/S0021-9150(98)00032-X","article-title":"Atorvastatin and gemfibrozil metabolites, but not the parent drugs, are potent antioxidants against lipoprotein oxidation","volume":"138","author":"Aviram","year":"1998","journal-title":"Atherosclerosis"},{"issue":"18","key":"10.1016\/j.jsps.2020.08.025_b0055","doi-asserted-by":"crossref","first-page":"1383","DOI":"10.1056\/NEJMra012519","article-title":"Bronchiectasis","volume":"346","author":"Barker","year":"2002","journal-title":"N. Engl. J. Med."},{"issue":"8","key":"10.1016\/j.jsps.2020.08.025_b0060","doi-asserted-by":"crossref","first-page":"857","DOI":"10.1513\/pats.200807-069TH","article-title":"Future treatments for chronic obstructive pulmonary disease and its comorbidities","volume":"5","author":"Barnes","year":"2008","journal-title":"Proc. Am. Thoracic Soc."},{"issue":"9410","key":"10.1016\/j.jsps.2020.08.025_b0065","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1016\/S0140-6736(04)15650-X","article-title":"Corticosteroid resistance in chronic obstructive pulmonary disease: inactivation of histone deacetylase","volume":"363","author":"Barnes","year":"2004","journal-title":"The Lancet"},{"issue":"3","key":"10.1016\/j.jsps.2020.08.025_b0070","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1023\/A:1011908004965","article-title":"Safety of HMG-CoA reductase inhibitors: focus on atorvastatin","volume":"15","author":"Bernini","year":"2001","journal-title":"Cardiovasc. Drugs Ther."},{"issue":"9","key":"10.1016\/j.jsps.2020.08.025_b0075","doi-asserted-by":"crossref","first-page":"1373","DOI":"10.1111\/j.1742-1241.2008.01731.x","article-title":"Statins may reduce episodes of exacerbation and the requirement for intubation in patients with COPD: evidence from a retrospective cohort study","volume":"62","author":"Blamoun","year":"2008","journal-title":"Int. J. Clin. Pract."},{"key":"10.1016\/j.jsps.2020.08.025_b0080","doi-asserted-by":"crossref","first-page":"620","DOI":"10.3389\/fimmu.2016.00620","article-title":"Increase of frequency and modulation of phenotype of regulatory T cells by atorvastatin is associated with decreased lung inflammatory cell infiltration in a murine model of acute allergic asthma","volume":"7","author":"Blanquiceth","year":"2016","journal-title":"Front. Immunol."},{"issue":"5","key":"10.1016\/j.jsps.2020.08.025_b0085","doi-asserted-by":"crossref","first-page":"2240","DOI":"10.1002\/jps.21995","article-title":"Drug transporters in the lung\u2014do they play a role in the biopharmaceutics of inhaled drugs?","volume":"99","author":"Bosquillon","year":"2010","journal-title":"J. Pharm. Sci."},{"key":"10.1016\/j.jsps.2020.08.025_b0090","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1016\/j.addr.2018.06.005","article-title":"Repurposing of statins via inhalation to treat lung inflammatory conditions","volume":"133","author":"Bradbury","year":"2018","journal-title":"Adv. Drug Deliv. Rev."},{"issue":"1","key":"10.1016\/j.jsps.2020.08.025_b0095","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1186\/1471-2466-11-16","article-title":"Effects of short-term treatment with atorvastatin in smokers with asthma-a randomized controlled trial","volume":"11","author":"Braganza","year":"2011","journal-title":"BMC Pulmonary Med."},{"issue":"2","key":"10.1016\/j.jsps.2020.08.025_b0100","doi-asserted-by":"crossref","first-page":"368","DOI":"10.1093\/oxfordjournals.bmb.a072967","article-title":"Cytokine expression in chronic inflammatory disease","volume":"51","author":"Brennan","year":"1995","journal-title":"Br. Med. Bull."},{"issue":"2","key":"10.1016\/j.jsps.2020.08.025_b0105","doi-asserted-by":"crossref","first-page":"153","DOI":"10.2165\/00002512-200320020-00006","article-title":"Comparison of the efficacy and tolerability of policosanol with atorvastatin in elderly patients with type II hypercholesterolaemia","volume":"20","author":"Casta\u00f1o","year":"2003","journal-title":"Drugs Aging"},{"issue":"9","key":"10.1016\/j.jsps.2020.08.025_b0110","doi-asserted-by":"crossref","DOI":"10.1038\/cddis.2013.312","article-title":"Atorvastatin overcomes gefitinib resistance in KRAS mutant human non-small cell lung carcinoma cells","volume":"4","author":"Chen","year":"2013","journal-title":"Cell Death Dis."},{"issue":"5","key":"10.1016\/j.jsps.2020.08.025_b0115","doi-asserted-by":"crossref","first-page":"759","DOI":"10.1016\/j.biocel.2012.01.015","article-title":"Atorvastatin sensitizes human non-small cell lung carcinomas to carboplatin via suppression of AKT activation and upregulation of TIMP-1","volume":"44","author":"Chen","year":"2012","journal-title":"Int. J. Biochem. Cell Biol."},{"issue":"1","key":"10.1016\/j.jsps.2020.08.025_b0120","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1016\/j.molonc.2011.11.003","article-title":"Atorvastatin reduces vascular endothelial growth factor (VEGF) expression in human non-small cell lung carcinomas (NSCLCs) via inhibition of reactive oxygen species (ROS) production","volume":"6","author":"Chen","year":"2012","journal-title":"Mol. Oncol."},{"issue":"4","key":"10.1016\/j.jsps.2020.08.025_b0125","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1016\/j.apsb.2012.05.002","article-title":"Development and characterization of an atorvastatin solid dispersion formulation using skimmed milk for improved oral bioavailability","volume":"2","author":"Choudhary","year":"2012","journal-title":"Acta Pharm. Sin. B"},{"key":"10.1016\/j.jsps.2020.08.025_b0130","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1016\/j.ejphar.2015.09.009","article-title":"Atorvastatin along with imipenem attenuates acute lung injury in sepsis through decrease in inflammatory mediators and bacterial load","volume":"765","author":"Choudhury","year":"2015","journal-title":"Eur. J. Pharmacol."},{"issue":"6","key":"10.1016\/j.jsps.2020.08.025_b0135","doi-asserted-by":"crossref","first-page":"1334","DOI":"10.1183\/09031936.00018908","article-title":"Multifaceted mechanisms in COPD: inflammation, immunity, and tissue repair and destruction","volume":"31","author":"Chung","year":"2008","journal-title":"Eur. Respir. J."},{"key":"10.1016\/j.jsps.2020.08.025_b0140","unstructured":"Collaboration, C.T.T., 2015. Efficacy and safety of LDL\u2010lowering therapy among men and women: meta\u2010analysis of individual data from 174,000 participants in 27 randomised trials."},{"issue":"3","key":"10.1016\/j.jsps.2020.08.025_b0145","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1016\/S0163-7258(99)00045-5","article-title":"New insights into the pharmacodynamic and pharmacokinetic properties of statins","volume":"84","author":"Corsini","year":"1999","journal-title":"Pharmacol. Ther."},{"issue":"6","key":"10.1016\/j.jsps.2020.08.025_b0150","doi-asserted-by":"crossref","first-page":"935","DOI":"10.1016\/j.cell.2010.02.043","article-title":"Anti-inflammatory agents: present and future","volume":"140","author":"Dinarello","year":"2010","journal-title":"Cell"},{"key":"10.1016\/j.jsps.2020.08.025_b0155","doi-asserted-by":"crossref","unstructured":"Drost, E., Selby, C., Lannan, S., Lowe, G., MacNee, W., 1992. Changes in neutrophil deformability following in vitro smoke exposure: mechanism and protection.","DOI":"10.1165\/ajrcmb\/6.3.287"},{"key":"10.1016\/j.jsps.2020.08.025_b0160","first-page":"1","article-title":"Immune modulatory effects of hypercholesterolemia: can atorvastatin convert the detrimental effect of hypercholesterolemia on the immune system?","author":"Emruzi","year":"2018","journal-title":"Iran. J. Allergy Asthma Immunol."},{"key":"10.1016\/j.jsps.2020.08.025_b0165","series-title":"Paper presented at the International Congress Series","article-title":"The origin of the statins","author":"Endo","year":"2004"},{"issue":"12","key":"10.1016\/j.jsps.2020.08.025_b0170","doi-asserted-by":"crossref","first-page":"1346","DOI":"10.7164\/antibiotics.29.1346","article-title":"ML-236A, ML-236B, and ML-236C, new inhibitors of cholesterogensis produced by Penicillium citrinum","volume":"29","author":"Endo","year":"1976","journal-title":"J. Antibiotics"},{"issue":"1","key":"10.1016\/j.jsps.2020.08.025_b0175","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1111\/j.1432-1033.1977.tb11637.x","article-title":"Inhibition of Cholesterol Synthesis in vitro and in vivo by ML-236A and ML-236B, Competitive Inhibitors of 3-Hydroxy-3-methylglutaryl-Coenzyme A Reductase","volume":"77","author":"Endo","year":"1977","journal-title":"Eur. J. Biochem."},{"issue":"1","key":"10.1016\/j.jsps.2020.08.025_b0180","first-page":"13","article-title":"Do statins improve lung function in asthmatic patients? A randomized and double-blind trial","volume":"5","author":"Fahimi","year":"2009","journal-title":"Iran. J. Pharm. Sci."},{"issue":"2","key":"10.1016\/j.jsps.2020.08.025_b0185","doi-asserted-by":"crossref","first-page":"1016","DOI":"10.3892\/or.2016.4897","article-title":"Atorvastatin partially inhibits the epithelial-mesenchymal transition in A549 cells induced by TGF-\u03b21 by attenuating the upregulation of SphK1","volume":"36","author":"Fan","year":"2016","journal-title":"Oncol. Rep."},{"issue":"5","key":"10.1016\/j.jsps.2020.08.025_b0190","doi-asserted-by":"crossref","first-page":"1355","DOI":"10.1007\/s10753-014-9860-y","article-title":"Oxidative stress and inflammation are differentially affected by atorvastatin, pravastatin, rosuvastatin, and simvastatin on lungs from mice exposed to cigarette smoke","volume":"37","author":"Ferreira","year":"2014","journal-title":"Inflammation"},{"issue":"4","key":"10.1016\/j.jsps.2020.08.025_b0195","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1016\/j.aller.2013.09.002","article-title":"The effect of atorvastatin on lung histopathology in a murine model of chronic asthma","volume":"42","author":"F\u0131r\u0131nc\u0131","year":"2014","journal-title":"Allergol. Immunopathol."},{"issue":"9","key":"10.1016\/j.jsps.2020.08.025_b0200","doi-asserted-by":"crossref","first-page":"823","DOI":"10.1016\/j.amjhyper.2004.06.005","article-title":"Effect of amlodipine\u2013atorvastatin combination on fibrinolysis in hypertensive hypercholesterolemic patients with insulin resistance","volume":"17","author":"Fogari","year":"2004","journal-title":"Am. J. Hypertens."},{"issue":"3","key":"10.1016\/j.jsps.2020.08.025_b0205","first-page":"84","article-title":"Effect of statins on fibroblasts from human nasal polyps and turbinates","volume":"40","author":"Folli","year":"2008","journal-title":"Eur. Ann. Allergy.. Clin. Immunol."},{"issue":"1","key":"10.1016\/j.jsps.2020.08.025_b0210","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1124\/pr.111.004994","article-title":"Pharmacological actions of statins: a critical appraisal in the management of cancer","volume":"64","author":"Gazzerro","year":"2012","journal-title":"Pharmacol. Rev."},{"issue":"6","key":"10.1016\/j.jsps.2020.08.025_b0215","doi-asserted-by":"crossref","first-page":"453","DOI":"10.18553\/jmcp.2002.8.6.453","article-title":"Effects of a tablet-splitting program in patients taking HMG-CoA reductase inhibitors: analysis of clinical effects, patient satisfaction, compliance, and cost avoidance","volume":"8","author":"Gee","year":"2002","journal-title":"J. Managed Care Pharmacy"},{"issue":"2","key":"10.1016\/j.jsps.2020.08.025_b0220","first-page":"99","article-title":"The effects of atorvastatin on mustard-gas-exposed patients with chronic obstructive pulmonary disease: a randomized controlled trial","volume":"19","author":"Ghobadi","year":"2014","journal-title":"J. Res. Med. Sci.: Off. J. Isfahan Univ. Med. Sci."},{"issue":"2","key":"10.1016\/j.jsps.2020.08.025_b0225","doi-asserted-by":"crossref","first-page":"G315","DOI":"10.1152\/ajpgi.1999.276.2.G315","article-title":"I. Physiological chemistry of nitric oxide and its metabolites: implications in inflammation","volume":"276","author":"Grisham","year":"1999","journal-title":"Am. J. Physiol.-Gastrointestinal Liver Physiol."},{"issue":"6","key":"10.1016\/j.jsps.2020.08.025_b0230","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0038917","article-title":"Simvastatin reduces endotoxin-induced acute lung injury by decreasing neutrophil recruitment and radical formation","volume":"7","author":"Grommes","year":"2012","journal-title":"PLoS ONE"},{"issue":"10","key":"10.1016\/j.jsps.2020.08.025_b0235","doi-asserted-by":"crossref","first-page":"894","DOI":"10.1136\/thx.2008.110619","article-title":"Chronic bronchitis before age 50 years predicts incident airflow limitation and mortality risk","volume":"64","author":"Guerra","year":"2009","journal-title":"Thorax"},{"key":"10.1016\/j.jsps.2020.08.025_b0240","unstructured":"Guideline, I.H.T., 2003. Stability testing of new drug substances and products. Q1A (R2), current step, 4."},{"issue":"7","key":"10.1016\/j.jsps.2020.08.025_b0245","doi-asserted-by":"crossref","first-page":"2061","DOI":"10.1016\/S0735-1097(99)00495-7","article-title":"Effect of high-versus low-dose angiotensin converting enzyme inhibition on cytokine levels in chronic heart failure","volume":"34","author":"Gullestad","year":"1999","journal-title":"J. Am. Coll. Cardiol."},{"issue":"4","key":"10.1016\/j.jsps.2020.08.025_b0250","doi-asserted-by":"crossref","DOI":"10.17795\/jjnpp-13370","article-title":"Ameliorative effects of atorvastatin on bleomycin-induced pulmonary fibrosis in rats","volume":"11","author":"Hemmeti","year":"2016","journal-title":"Jundishapur J. Nat. Pharm. Prod."},{"issue":"6","key":"10.1016\/j.jsps.2020.08.025_b0255","doi-asserted-by":"crossref","first-page":"532","DOI":"10.1016\/j.clpt.2006.02.014","article-title":"Exposure of atorvastatin is unchanged but lactone and acid metabolites are increased several-fold in patients with atorvastatin-induced myopathy","volume":"79","author":"Hermann","year":"2006","journal-title":"Clin. Pharmacol. Ther."},{"issue":"5","key":"10.1016\/j.jsps.2020.08.025_b0260","doi-asserted-by":"crossref","first-page":"1595","DOI":"10.1111\/j.1476-5381.2011.01665.x","article-title":"Effects of atorvastatin metabolites on induction of drug-metabolizing enzymes and membrane transporters through human pregnane X receptor","volume":"165","author":"Hoffart","year":"2012","journal-title":"Br. J. Pharmacol."},{"issue":"5","key":"10.1016\/j.jsps.2020.08.025_b0265","doi-asserted-by":"crossref","first-page":"849","DOI":"10.1021\/jm00155a040","article-title":"3-Hydroxy-3-methylglutaryl-coenzyme A reductase inhibitors. 4. Side-chain ester derivatives of mevinolin","volume":"29","author":"Hoffman","year":"1986","journal-title":"J. Med. Chem."},{"issue":"8","key":"10.1016\/j.jsps.2020.08.025_b0270","doi-asserted-by":"crossref","first-page":"729","DOI":"10.1136\/thx.2005.057976","article-title":"Potential therapeutic role for statins in respiratory disease","volume":"61","author":"Hothersall","year":"2006","journal-title":"Thorax"},{"key":"10.1016\/j.jsps.2020.08.025_b0275","unstructured":"Hothersall, E.J., 2008. Effect of atorvastatin on asthma control and airway inflammation: a randomised controlled trial. University of Glasgow, Retrieved from http:\/\/europepmc.org\/theses\/ETH\/495335 EThOS database."},{"issue":"12","key":"10.1016\/j.jsps.2020.08.025_b0280","doi-asserted-by":"crossref","first-page":"1070","DOI":"10.1136\/thx.2008.100198","article-title":"Effects of atorvastatin added to inhaled corticosteroids on lung function and sputum cell counts in atopic asthma","volume":"63","author":"Hothersall","year":"2008","journal-title":"Thorax"},{"key":"10.1016\/j.jsps.2020.08.025_b0285","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1042\/bj3180319","article-title":"Different mucins are produced by the surface epithelium and the submucosa in human trachea: identification of MUC5AC as a major mucin from the goblet cells","volume":"318","author":"Hovenberg","year":"1996","journal-title":"Biochem. J"},{"issue":"1","key":"10.1016\/j.jsps.2020.08.025_b0290","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/j.anai.2012.09.002","article-title":"Effect of oral administration with pravastatin and atorvastatin on airway hyperresponsiveness and allergic reactions in asthmatic mice","volume":"110","author":"Huang","year":"2013","journal-title":"Ann. Allergy Asthma Immunol."},{"issue":"1","key":"10.1016\/j.jsps.2020.08.025_b0295","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1016\/j.ejpb.2004.03.016","article-title":"Pulmonary delivery of therapeutic peptides via dry powder inhalation: effects of micronisation and manufacturing","volume":"58","author":"Irngartinger","year":"2004","journal-title":"Eur. J. Pharm. Biopharm."},{"issue":"3","key":"10.1016\/j.jsps.2020.08.025_b0300","first-page":"282","article-title":"A comparison of the effects of 3-hydroxy-3-methylglutaryl-coenzyme a (HMG-CoA) reductase inhibitors on the CYP3A4-dependent oxidation of mexazolam in vitro","volume":"29","author":"Ishigami","year":"2001","journal-title":"Drug Metab. Dispos."},{"issue":"11","key":"10.1016\/j.jsps.2020.08.025_b0305","first-page":"1369","article-title":"Lactonization is the critical first step in the disposition of the 3-hydroxy-3-methylglutaryl-CoA reductase inhibitor atorvastatin","volume":"28","author":"Jacobsen","year":"2000","journal-title":"Drug Metab. Dispos."},{"issue":"1","key":"10.1016\/j.jsps.2020.08.025_b0310","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1183\/09031936.00146905","article-title":"Clinical relevance of airway remodelling in airway diseases","volume":"30","author":"James","year":"2007","journal-title":"Eur. Respir. J."},{"issue":"15","key":"10.1016\/j.jsps.2020.08.025_b0315","doi-asserted-by":"crossref","first-page":"1933","DOI":"10.1161\/01.CIR.103.15.1933","article-title":"Effect of hydroxymethyl glutaryl coenzyme a reductase inhibitor therapy on high sensitive C-reactive protein levels","volume":"103","author":"Jialal","year":"2001","journal-title":"Circulation"},{"issue":"6","key":"10.1016\/j.jsps.2020.08.025_b0320","doi-asserted-by":"crossref","first-page":"1764","DOI":"10.1378\/chest.07-0298","article-title":"The use of statins and lung function in current and former smokers","volume":"132","author":"Keddissi","year":"2007","journal-title":"Chest"},{"issue":"4","key":"10.1016\/j.jsps.2020.08.025_b0325","doi-asserted-by":"crossref","first-page":"1077","DOI":"10.1208\/s12249-011-9673-3","article-title":"Enhanced bioavailability of atorvastatin calcium from stabilized gastric resident formulation","volume":"12","author":"Khan","year":"2011","journal-title":"AAPS PharmSciTech"},{"issue":"4","key":"10.1016\/j.jsps.2020.08.025_b0330","first-page":"345","article-title":"The preventive effect of atorvastatin on paraquat-induced pulmonary fibrosis in the rats","volume":"4","author":"Khodayar","year":"2014","journal-title":"Adv. Pharm. Bull."},{"issue":"1\u20132","key":"10.1016\/j.jsps.2020.08.025_b0335","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1016\/j.ijpharm.2008.04.006","article-title":"Physicochemical properties and oral bioavailability of amorphous atorvastatin hemi-calcium using spray-drying and SAS process","volume":"359","author":"Kim","year":"2008","journal-title":"Int. J. Pharm."},{"issue":"8","key":"10.1016\/j.jsps.2020.08.025_b0340","doi-asserted-by":"crossref","first-page":"1914","DOI":"10.1183\/09031936.97.10081914","article-title":"Lung mucus: a clinician's view","volume":"10","author":"Kim","year":"1997","journal-title":"Eur. Respir. J."},{"key":"10.1016\/j.jsps.2020.08.025_b0345","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1042\/bj3610537","article-title":"Heterogeneity of airways mucus: variations in the amounts and glycoforms of the major oligomeric mucins MUC5AC and MUC5B","volume":"361","author":"Kirkham","year":"2002","journal-title":"Biochem. J"},{"issue":"7","key":"10.1016\/j.jsps.2020.08.025_b0350","doi-asserted-by":"crossref","first-page":"857","DOI":"10.1081\/DDC-100102246","article-title":"Trends in stability testing, with emphasis on stability during distribution and storage","volume":"25","author":"Kommanaboyina","year":"1999","journal-title":"Drug Dev. Ind. Pharm."},{"issue":"2","key":"10.1016\/j.jsps.2020.08.025_b0355","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1016\/j.pupt.2012.10.008","article-title":"Statins, systemic inflammation and risk of death in COPD: the Rotterdam study","volume":"26","author":"Lahousse","year":"2013","journal-title":"Pulm. Pharmacol. Ther."},{"issue":"7","key":"10.1016\/j.jsps.2020.08.025_b0360","doi-asserted-by":"crossref","first-page":"1175","DOI":"10.1124\/dmd.105.009076","article-title":"Pharmacokinetics of atorvastatin and its hydroxy metabolites in rats and the effects of concomitant rifampicin single doses: relevance of first-pass effect from hepatic uptake transporters, and intestinal and hepatic metabolism","volume":"34","author":"Lau","year":"2006","journal-title":"Drug Metab. Dispos."},{"issue":"5","key":"10.1016\/j.jsps.2020.08.025_b0365","doi-asserted-by":"crossref","first-page":"828","DOI":"10.2165\/00003495-199753050-00011","article-title":"Atorvastatin","volume":"53","author":"Lea","year":"1997","journal-title":"Drugs"},{"issue":"8","key":"10.1016\/j.jsps.2020.08.025_b0370","doi-asserted-by":"crossref","first-page":"2474","DOI":"10.1021\/jm00112a024","article-title":"3-Hydroxy-3-methylglutaryl-coenzyme A reductase inhibitors. 8. Side chain ether analogs of lovastatin","volume":"34","author":"Lee","year":"1991","journal-title":"J. Med. Chem."},{"issue":"13","key":"10.1016\/j.jsps.2020.08.025_b0375","doi-asserted-by":"crossref","first-page":"1141","DOI":"10.2165\/00003088-200342130-00005","article-title":"Clinical pharmacokinetics of atorvastatin","volume":"42","author":"Lennern\u00e4s","year":"2003","journal-title":"Clin. Pharmacokinet."},{"issue":"1","key":"10.1016\/j.jsps.2020.08.025_b0380","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1111\/j.1755-5922.2009.00103.x","article-title":"Atorvastatin decreases C-reactive protein-induced inflammatory response in pulmonary artery smooth muscle cells by inhibiting nuclear factor-\u03baB pathway","volume":"28","author":"Li","year":"2010","journal-title":"Cardiovasc. Therap."},{"issue":"1","key":"10.1016\/j.jsps.2020.08.025_b0385","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1111\/j.1749-6632.2002.tb04077.x","article-title":"Role of nitric oxide in inflammation-mediated neurodegeneration","volume":"962","author":"Liu","year":"2002","journal-title":"Ann. New York Acad. Sci."},{"issue":"37","key":"10.1016\/j.jsps.2020.08.025_b0390","doi-asserted-by":"crossref","first-page":"59618","DOI":"10.18632\/oncotarget.11162","article-title":"Statins dose-dependently exert a chemopreventive effect against lung cancer in COPD patients: a population-based cohort study","volume":"7","author":"Liu","year":"2016","journal-title":"Oncotarget"},{"issue":"1","key":"10.1016\/j.jsps.2020.08.025_b0395","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1080\/01926230601060025","article-title":"Cystic fibrosis and other respiratory diseases of impaired mucus clearance","volume":"35","author":"Livraghi","year":"2007","journal-title":"Toxicol. Pathol."},{"issue":"15","key":"10.1016\/j.jsps.2020.08.025_b0400","doi-asserted-by":"crossref","first-page":"4981","DOI":"10.1158\/1078-0432.CCR-07-1860","article-title":"Synergistic inhibition of lung tumorigenesis by a combination of green tea polyphenols and atorvastatin","volume":"14","author":"Lu","year":"2008","journal-title":"Clin. Cancer Res."},{"issue":"2","key":"10.1016\/j.jsps.2020.08.025_b0405","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1016\/0091-6749(90)90147-V","article-title":"Pathogenesis of airway mucus hypersecretion","volume":"85","author":"Lundgren","year":"1990","journal-title":"J. Allergy Clin. Immunol."},{"issue":"1","key":"10.1016\/j.jsps.2020.08.025_b0410","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1016\/S0014-2999(01)01320-6","article-title":"Oxidative stress and lung inflammation in airways disease","volume":"429","author":"MacNee","year":"2001","journal-title":"Eur. J. Pharmacol."},{"issue":"6","key":"10.1016\/j.jsps.2020.08.025_b0415","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1016\/S2213-2600(14)70050-5","article-title":"Atorvastatin as a stable treatment in bronchiectasis: a randomised controlled trial","volume":"2","author":"Mandal","year":"2014","journal-title":"Lancet Respiratory Med."},{"issue":"4","key":"10.1016\/j.jsps.2020.08.025_b0420","doi-asserted-by":"crossref","first-page":"504","DOI":"10.4103\/ijem.IJEM_79_17","article-title":"Myopathy in patients taking atorvastatin: a pilot study","volume":"21","author":"Manoj","year":"2017","journal-title":"Indian J. Endocrinol. Metab."},{"issue":"9","key":"10.1016\/j.jsps.2020.08.025_b0425","doi-asserted-by":"crossref","first-page":"1205","DOI":"10.1517\/17425247.2011.588697","article-title":"Chronic obstructive pulmonary disease: patho-physiology, current methods of treatment and the potential for simvastatin in disease management","volume":"8","author":"Marin","year":"2011","journal-title":"Expert Opinion Drug Deliv."},{"issue":"3","key":"10.1016\/j.jsps.2020.08.025_b0430","doi-asserted-by":"crossref","first-page":"566","DOI":"10.1016\/j.ejpb.2013.01.021","article-title":"Multiple dosing of simvastatin inhibits airway mucus production of epithelial cells: implications in the treatment of chronic obstructive airway pathologies","volume":"84","author":"Marin","year":"2013","journal-title":"Eur. J. Pharm. Biopharm."},{"issue":"1","key":"10.1016\/j.jsps.2020.08.025_b0435","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1186\/1471-2466-13-47","article-title":"Simvastatin decreases the level of heparin-binding protein in patients with acute lung injury","volume":"13","author":"McAuley","year":"2013","journal-title":"BMC Pulmonary Med."},{"key":"10.1016\/j.jsps.2020.08.025_b0440","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1016\/j.biopha.2018.03.067","article-title":"Atorvastatin dose-dependently promotes mouse lung repair after emphysema induced by elastase","volume":"102","author":"Melo","year":"2018","journal-title":"Biomed. Pharmacother."},{"issue":"1","key":"10.1016\/j.jsps.2020.08.025_b0445","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/j.intimp.2013.05.016","article-title":"Redox markers and inflammation are differentially affected by atorvastatin, pravastatin or simvastatin administered before endotoxin-induced acute lung injury","volume":"17","author":"Melo","year":"2013","journal-title":"Int. Immunopharmacol."},{"issue":"4","key":"10.1016\/j.jsps.2020.08.025_b0450","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1097\/01.ccx.0000235207.00322.96","article-title":"Statins in the intensive care unit","volume":"12","author":"Merx","year":"2006","journal-title":"Curr. Opin. Critical Care"},{"issue":"26","key":"10.1016\/j.jsps.2020.08.025_b0455","doi-asserted-by":"crossref","first-page":"3901","DOI":"10.2174\/138161212802083743","article-title":"Tobacco, inflammation, and respiratory tract cancer","volume":"18","author":"Milara","year":"2012","journal-title":"Curr. Pharm. Des."},{"issue":"5","key":"10.1016\/j.jsps.2020.08.025_b0460","doi-asserted-by":"crossref","first-page":"290","DOI":"10.4168\/aair.2012.4.5.290","article-title":"Evaluation of atorvastatin for the treatment of patients with asthma: a double-blind randomized clinical trial","volume":"4","author":"Moini","year":"2012","journal-title":"Allergy Asthma Immunol. Res."},{"issue":"1","key":"10.1016\/j.jsps.2020.08.025_b0465","first-page":"111","article-title":"Anti-inflammatory effects of atorvastatin treatment in chronic obstructive pulmonary disease. A controlled pilot study","volume":"66","author":"Mroz","year":"2015","journal-title":"J. Physiol. Pharmacol."},{"issue":"1","key":"10.1016\/j.jsps.2020.08.025_b0470","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1097\/MOP.0b013e3280123a5d","article-title":"Pseudomonas aeruginosa chronic colonization in cystic fibrosis patients","volume":"19","author":"Murray","year":"2007","journal-title":"Curr. Opin. Pediatr."},{"issue":"4","key":"10.1016\/j.jsps.2020.08.025_b0475","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1016\/j.trac.2008.01.013","article-title":"HPLC methods for the determination of simvastatin and atorvastatin","volume":"27","author":"Nov\u00e1kov\u00e1","year":"2008","journal-title":"TrAC, Trends Anal. Chem."},{"issue":"2","key":"10.1016\/j.jsps.2020.08.025_b0480","doi-asserted-by":"crossref","first-page":"1447","DOI":"10.3390\/molecules18021447","article-title":"Degradation kinetics of atorvastatin under stress conditions and chemical analysis by HPLC","volume":"18","author":"Oliveira","year":"2013","journal-title":"Molecules"},{"issue":"9","key":"10.1016\/j.jsps.2020.08.025_b0485","doi-asserted-by":"crossref","first-page":"1240","DOI":"10.1080\/00498250802334391","article-title":"Contribution of cytochrome P450 3A4 and 3A5 to the metabolism of atorvastatin","volume":"38","author":"Park","year":"2008","journal-title":"Xenobiotica"},{"issue":"6","key":"10.1016\/j.jsps.2020.08.025_b0490","doi-asserted-by":"crossref","first-page":"1468","DOI":"10.1007\/s10753-013-9688-x","article-title":"Antihyperalgesic and anti-inflammatory effects of atorvastatin in chronic constriction injury-induced neuropathic pain in rats","volume":"36","author":"Pathak","year":"2013","journal-title":"Inflammation"},{"issue":"1","key":"10.1016\/j.jsps.2020.08.025_b0495","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.ijpharm.2010.03.017","article-title":"Formulation strategy and use of excipients in pulmonary drug delivery","volume":"392","author":"Pilcer","year":"2010","journal-title":"Int. J. Pharm."},{"issue":"3","key":"10.1016\/j.jsps.2020.08.025_b0500","doi-asserted-by":"crossref","first-page":"965","DOI":"10.1007\/s10753-017-0541-5","article-title":"Atorvastatin and simvastatin promoted mouse lung repair after cigarette smoke-induced emphysema","volume":"40","author":"Pinho-Ribeiro","year":"2017","journal-title":"Inflammation"},{"issue":"1","key":"10.1016\/j.jsps.2020.08.025_b0505","doi-asserted-by":"crossref","first-page":"3","DOI":"10.2165\/00003495-200767001-00002","article-title":"Atorvastatin","volume":"67","author":"Poli","year":"2007","journal-title":"Drugs"},{"key":"10.1016\/j.jsps.2020.08.025_b0510","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1289\/ehp.8347345","article-title":"Electron-spin resonance study of mainstream and sidestream cigarette smoke: nature of the free radicals in gas-phase smoke and in cigarette tar","volume":"47","author":"Pryor","year":"1983","journal-title":"Environ. Health Perspect."},{"issue":"3","key":"10.1016\/j.jsps.2020.08.025_b0515","doi-asserted-by":"crossref","first-page":"534","DOI":"10.1034\/j.1399-3003.2000.016003534.x","article-title":"Oxidative stress and regulation of glutathione in lung inflammation","volume":"16","author":"Rahman","year":"2000","journal-title":"Eur. Respir. J."},{"issue":"3","key":"10.1016\/j.jsps.2020.08.025_b0520","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1007\/s00210-006-0112-z","article-title":"The protective effect of HMG-CoA reductase inhibitors against monocrotaline-induced pulmonary hypertension in the rat might not be a class effect: comparison of pravastatin and atorvastatin","volume":"374","author":"Rakotoniaina","year":"2006","journal-title":"Naunyn-Schmiedeberg's Arch. Pharmacol."},{"issue":"5","key":"10.1016\/j.jsps.2020.08.025_b0525","doi-asserted-by":"crossref","first-page":"592","DOI":"10.1165\/ajrcmb.17.5.2798","article-title":"Developmental expression of mucin genes in the human respiratory tract","volume":"17","author":"Reid","year":"1997","journal-title":"Am. J. Respir. Cell Mol. Biol."},{"issue":"7","key":"10.1016\/j.jsps.2020.08.025_b0530","doi-asserted-by":"crossref","first-page":"1194","DOI":"10.1161\/01.ATV.0000022694.16328.CC","article-title":"Simvastatin reduces expression of cytokines interleukin-6, interleukin-8, and monocyte chemoattractant protein-1 in circulating monocytes from hypercholesterolemic patients","volume":"22","author":"Rezaie-Majd","year":"2002","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"key":"10.1016\/j.jsps.2020.08.025_b0535","doi-asserted-by":"crossref","DOI":"10.1155\/2014\/463895","article-title":"Solubility and bioavailability enhancement of poorly aqueous soluble atorvastatin: in vitro, ex vivo, and in vivo studies","volume":"2014","author":"Rodde","year":"2014","journal-title":"BioMed Res. Int."},{"issue":"1","key":"10.1016\/j.jsps.2020.08.025_b0540","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1016\/j.ijcard.2007.01.040","article-title":"Comparisons of short-and intermediate-term effects of pitavastatin versus atorvastatin on lipid profiles, fibrinolytic parameter, and endothelial function","volume":"125","author":"Sakabe","year":"2008","journal-title":"Int. J. Cardiol."},{"issue":"6","key":"10.1016\/j.jsps.2020.08.025_b0545","doi-asserted-by":"crossref","first-page":"754","DOI":"10.4103\/0250-474X.49117","article-title":"Stability indicating RP-HPLC estimation of atorvastatin calcium and amlodipine besylate in pharmaceutical formulations","volume":"70","author":"Shah","year":"2008","journal-title":"Indian J. Pharm. Sci."},{"issue":"1","key":"10.1016\/j.jsps.2020.08.025_b0550","doi-asserted-by":"crossref","first-page":"22","DOI":"10.4103\/2231-4040.169873","article-title":"Atorvastatin solid dispersion for bioavailability enhancement","volume":"7","author":"Shamsuddin","year":"2016","journal-title":"J. Adv. Pharm. Technol. Res."},{"key":"10.1016\/j.jsps.2020.08.025_b0555","first-page":"1","article-title":"Simvastatin downregulates expression of TGF-\u03b2RII and inhibits proliferation of A549 cells via ERK","author":"Shang","year":"2015","journal-title":"Tumor Biol."},{"issue":"1","key":"10.1016\/j.jsps.2020.08.025_b0560","doi-asserted-by":"crossref","first-page":"195","DOI":"10.3797\/scipharm.1210-19","article-title":"Comprehensive assessment of degradation behavior of aspirin and atorvastatin singly and in combination by using a validated RP-HPLC method","volume":"81","author":"Sherikar","year":"2012","journal-title":"Sci. Pharm."},{"issue":"5","key":"10.1016\/j.jsps.2020.08.025_b0565","doi-asserted-by":"crossref","first-page":"1321","DOI":"10.1097\/CCM.0b013e3181d9dad6","article-title":"Pretreatment with atorvastatin attenuates lung injury caused by high-stretch mechanical ventilation in an isolated rabbit lung model","volume":"38","author":"Siempos","year":"2010","journal-title":"Crit. Care Med."},{"issue":"10","key":"10.1016\/j.jsps.2020.08.025_b0570","doi-asserted-by":"crossref","DOI":"10.1002\/bmc.4621","article-title":"Development and full validation of an HPLC methodology to quantify atorvastatin and curcumin after their intranasal co-delivery to mice","volume":"33","author":"Silva","year":"2019","journal-title":"Biomed. Chromatogr."},{"issue":"2","key":"10.1016\/j.jsps.2020.08.025_b0575","doi-asserted-by":"crossref","first-page":"438","DOI":"10.1016\/j.atherosclerosis.2006.07.020","article-title":"Anti-inflammatory effects of atorvastatin: modulation by the T-786C polymorphism in the endothelial nitric oxide synthase gene","volume":"193","author":"Souza-Costa","year":"2007","journal-title":"Atherosclerosis"},{"issue":"3","key":"10.1016\/j.jsps.2020.08.025_b0580","doi-asserted-by":"crossref","first-page":"343","DOI":"10.2174\/1567205054367900","article-title":"Atorvastatin therapy lowers circulating cholesterol but not free radical activity in advance of identifiable clinical benefit in the treatment of mild-to-moderate AD","volume":"2","author":"Sparks","year":"2005","journal-title":"Curr. Alzheimer Res."},{"issue":"3","key":"10.1016\/j.jsps.2020.08.025_b0585","first-page":"178","article-title":"An overview of statins as hypolipidemic drugs","volume":"3","author":"Srinivasa Rao","year":"2011","journal-title":"IJPSDR"},{"issue":"1","key":"10.1016\/j.jsps.2020.08.025_b0590","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1007\/BF02893433","article-title":"Pathology of chronic obstructive pulmonary disease","volume":"12","author":"Szilasi","year":"2006","journal-title":"Pathol. Oncol. Res."},{"issue":"10","key":"10.1016\/j.jsps.2020.08.025_b0595","doi-asserted-by":"crossref","first-page":"1429","DOI":"10.1172\/JCI13350","article-title":"Statins as antioxidant therapy for preventing cardiac myocyte hypertrophy","volume":"108","author":"Takemoto","year":"2001","journal-title":"J. Clin. Investig."},{"issue":"3","key":"10.1016\/j.jsps.2020.08.025_b0600","doi-asserted-by":"crossref","first-page":"e225","DOI":"10.1016\/j.thromres.2010.05.023","article-title":"Atorvastatin has antithrombotic effects in patients with type 1 diabetes and dyslipidemia","volume":"126","author":"Tehrani","year":"2010","journal-title":"Thromb. Res."},{"key":"10.1016\/j.jsps.2020.08.025_b0605","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.pupt.2015.01.001","article-title":"Atorvastatin in combination with inhaled beclometasone modulates inflammatory sputum mediators in smokers with asthma","volume":"31","author":"Thomson","year":"2015","journal-title":"Pulm. Pharmacol. Ther."},{"issue":"7","key":"10.1016\/j.jsps.2020.08.025_b0610","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1038\/nrd1112","article-title":"Lovastatin and beyond: the history of the HMG-CoA reductase inhibitors","volume":"2","author":"Tobert","year":"2003","journal-title":"Nat. Rev. Drug Discov."},{"issue":"2","key":"10.1016\/j.jsps.2020.08.025_b0615","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1208\/pt050226","article-title":"Effects of water vapor absorption on the physical and chemical stability of amorphous sodium indomethacin","volume":"5","author":"Tong","year":"2004","journal-title":"AAPS PharmSciTech"},{"issue":"4","key":"10.1016\/j.jsps.2020.08.025_b0620","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1185\/03007995.2013.865599","article-title":"Statin use in asthmatics on inhaled corticosteroids is associated with decreased risk of emergency department visits","volume":"30","author":"Tse","year":"2014","journal-title":"Curr. Med. Res. Opin."},{"issue":"10","key":"10.1016\/j.jsps.2020.08.025_b0625","doi-asserted-by":"crossref","first-page":"1407","DOI":"10.1080\/17425247.2016.1193150","article-title":"Could simvastatin be considered as a potential therapy for chronic lung diseases? A debate on the pros and cons","volume":"13","author":"Tulbah","year":"2016","journal-title":"Expert Opin. Drug Deliv."},{"key":"10.1016\/j.jsps.2020.08.025_b0630","first-page":"1","article-title":"Biological effects of simvastatin formulated as pMDI on pulmonary epithelial cells","author":"Tulbah","year":"2015","journal-title":"Pharm. Res."},{"issue":"6","key":"10.1016\/j.jsps.2020.08.025_b0635","doi-asserted-by":"crossref","first-page":"857","DOI":"10.1517\/17425247.2015.963054","article-title":"Dry powder formulation of simvastatin","volume":"12","author":"Tulbah","year":"2015","journal-title":"Expert opinion on drug delivery"},{"issue":"9","key":"10.1016\/j.jsps.2020.08.025_b0640","doi-asserted-by":"crossref","first-page":"1977","DOI":"10.1007\/s00125-007-0719-8","article-title":"Anti-inflammatory effects of atorvastatin improve left ventricular function in experimental diabetic cardiomyopathy","volume":"50","author":"Van Linthout","year":"2007","journal-title":"Diabetologia"},{"issue":"9034","key":"10.1016\/j.jsps.2020.08.025_b0645","doi-asserted-by":"crossref","first-page":"1079","DOI":"10.1016\/S0140-6736(96)05190-2","article-title":"Statins do more than just lower cholesterol","volume":"348","author":"Vaughan","year":"1996","journal-title":"The Lancet"},{"issue":"1","key":"10.1016\/j.jsps.2020.08.025_b0650","doi-asserted-by":"crossref","first-page":"93","DOI":"10.3797\/scipharm.1208-06","article-title":"Stress degradation behavior of atorvastatin calcium and development of a suitable stability-indicating LC method for the determination of atorvastatin, its related impurities, and its degradation products","volume":"81","author":"Vukkum","year":"2012","journal-title":"Sci. Pharm."},{"issue":"2","key":"10.1016\/j.jsps.2020.08.025_b0655","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1007\/s00280-011-1772-z","article-title":"The effect of bexarotene on atorvastatin pharmacokinetics: results from a phase I trial of bexarotene plus chemotherapy in patients with advanced non-small cell lung cancer","volume":"69","author":"Wakelee","year":"2012","journal-title":"Cancer Chemother. Pharmacol."},{"key":"10.1016\/j.jsps.2020.08.025_b0660","doi-asserted-by":"crossref","unstructured":"Walsh, G.M., 2008. Statins as emerging treatments for asthma and chronic obstructive pulmonary disease.","DOI":"10.1586\/17476348.2.3.329"},{"issue":"7","key":"10.1016\/j.jsps.2020.08.025_b0665","article-title":"The effects and mechanism of atorvastatin on pulmonary hypertension due to left heart disease","volume":"11","author":"Wang","year":"2016","journal-title":"PLoS ONE"},{"issue":"6","key":"10.1016\/j.jsps.2020.08.025_b0670","first-page":"5144","article-title":"Clinical significance and efficacy analysis of atorvastatin in the treatment of patients with cerebral infarction and aspiration pneumonia","volume":"16","author":"Wei","year":"2018","journal-title":"Exp. Therap. Med."},{"issue":"1","key":"10.1016\/j.jsps.2020.08.025_b0675","first-page":"64","article-title":"Effect of atorvastatin on MMP-9 and TIMP-1 levels in bronchoalveolar lavage fluid and serum of rats with bleomycin-induced pulmonary fibrosis","volume":"40","author":"Wei","year":"2011","journal-title":"Zhejiang da xue xue bao Yi xue ban = J. Zhejiang Univ. Med. Sci."},{"issue":"11","key":"10.1016\/j.jsps.2020.08.025_b0680","first-page":"1198","article-title":"Atorvastatin alleviates pulmonary fibrosis-induced by bleomycin in rats","volume":"29","author":"Wei","year":"2009","journal-title":"Basic Clin. Med."},{"issue":"5","key":"10.1016\/j.jsps.2020.08.025_b0685","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1165\/rcmb.2005-0436SF","article-title":"Airway mucus: from production to secretion","volume":"34","author":"Williams","year":"2006","journal-title":"Am. J. Respir. Cell Mol. Biol."},{"issue":"13","key":"10.1016\/j.jsps.2020.08.025_b0690","doi-asserted-by":"crossref","first-page":"1427","DOI":"10.1001\/archinte.164.13.1427","article-title":"Effectiveness of statin therapy in adults with coronary heart disease","volume":"164","author":"Wilt","year":"2004","journal-title":"Arch. Intern. Med."},{"issue":"6","key":"10.1016\/j.jsps.2020.08.025_b0695","doi-asserted-by":"crossref","first-page":"1441","DOI":"10.1002\/bit.23046","article-title":"Mannitol-Guided delivery of ciprofloxacin in artificial cystic fibrosis mucus model","volume":"108","author":"Yang","year":"2011","journal-title":"Biotechnol. Bioeng."},{"issue":"1","key":"10.1016\/j.jsps.2020.08.025_b0700","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1016\/j.pharmthera.2014.02.007","article-title":"Targeting the mevalonate cascade as a new therapeutic approach in heart disease, cancer and pulmonary disease","volume":"143","author":"Yeganeh","year":"2014","journal-title":"Pharmacol. Ther."},{"key":"10.1016\/j.jsps.2020.08.025_b0705","series-title":"Eur Respiratory Soc","article-title":"Anti-fibrotic effect of Atorvastatin on the lung fibroblasts and myofibroblasts","author":"Yildirim","year":"2018"},{"issue":"8","key":"10.1016\/j.jsps.2020.08.025_b0710","first-page":"351","article-title":"Simvastatin inhibits proliferation and induces apoptosis in human lung cancer cells","volume":"20","author":"Yu","year":"2013","journal-title":"Oncol. Res. Featuring Preclinical Clin. Cancer Therap."},{"issue":"10","key":"10.1016\/j.jsps.2020.08.025_b0715","first-page":"204","article-title":"Stability-indicating high performance liquid chromatographic determination of atorvastatin calcium in pharmaceutical dosage form","volume":"2","author":"Zaheer","year":"2008","journal-title":"African J. Pharm. Pharmacol."},{"issue":"1","key":"10.1016\/j.jsps.2020.08.025_b0720","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1111\/imm.12902","article-title":"Immune modulatory effects of statins","volume":"154","author":"Zeiser","year":"2018","journal-title":"Immunology"},{"issue":"8","key":"10.1016\/j.jsps.2020.08.025_b0725","article-title":"Statin use and asthma control in patients with severe asthma","volume":"3","author":"Zeki","year":"2013","journal-title":"BMJOpen"}],"container-title":["Saudi Pharmaceutical Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S131901642030205X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S131901642030205X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,1,6]],"date-time":"2025-01-06T17:23:28Z","timestamp":1736184208000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S131901642030205X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,11]]},"references-count":145,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2020,11]]}},"alternative-id":["S131901642030205X"],"URL":"https:\/\/doi.org\/10.1016\/j.jsps.2020.08.025","relation":{},"ISSN":["1319-0164"],"issn-type":[{"value":"1319-0164","type":"print"}],"subject":[],"published":{"date-parts":[[2020,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The potential of Atorvastatin for chronic lung diseases therapy","name":"articletitle","label":"Article Title"},{"value":"Saudi Pharmaceutical Journal","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jsps.2020.08.025","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 The Author(s). Published by Elsevier B.V. on behalf of King Saud University.","name":"copyright","label":"Copyright"}]}}